Urine has long carried the promise of a noninvasive window into kidney biology, but the practical challenge has been scale. Routine testing captures only a narrow slice of what is present, while disease processes in the kidney and throughout the body may leave much subtler protein signals behind. In this Kidney International study, investigators used the Olink Explore 3072 platform to quantify 2,868 proteins in urine samples from 1,268 participants in the German Chronic Kidney Disease study, creating one of the broader urinary protein surveys reported from a kidney disease cohort.

The work sits at the intersection of proteomics and nephrology. Urinary proteins are attractive because they can reflect glomerular injury, tubular dysfunction, inflammation, and systemic disease activity without requiring an invasive procedure. Yet urine is also a difficult specimen: proteins vary widely in abundance, and the proteome is shaped by filtration, reabsorption, secretion, and degradation before a sample ever reaches the assay platform. A large affinity-based panel such as Olink Explore 3072 gives researchers a way to ask a much more complete question about what the urine actually contains, rather than focusing on a handful of established markers.

The central finding was not simply the number of proteins detected, but the pattern of detectability itself. Protein detectability in urine, defined as the percentage of samples with measurements above the limit of detection, followed a bimodal distribution. In practical terms, the urinary proteome did not spread evenly across the assay range. Instead, some proteins appeared consistently across the cohort, while a much larger share was only intermittently measurable. Of the quantified proteins, 659 proteins, or 23%, showed high detectability above 80% of samples. Another 1,336 proteins, or 47%, fell into the low-detectability group.

A one-size-fits-all expectation for urinary biomarker assays does not survive that distribution.

This kind of split matters because detectability shapes what can be trusted in downstream biomarker work. Proteins present in most urine samples are better candidates for population-level comparisons, longitudinal tracking, and clinical assay development. Low-detectability proteins may still be biologically important, but they demand more caution: sparse measurements can reflect true biology, assay sensitivity limits, or both. In a chronic kidney disease cohort, those distinctions become especially important because kidney dysfunction can alter both protein handling and the composition of the urine matrix itself.

The study’s design also gives it clinical weight. The GCKD cohort is not a convenience sample of healthy volunteers; it is a kidney disease population in which urinary proteins are likely to be shaped by established renal pathology and by the broader metabolic and cardiovascular burden that often travels with chronic kidney disease. That setting makes the proteomic map more relevant to real-world nephrology than a purely experimental sample would be. The data therefore serve as a reference point for future work trying to distinguish abundant urinary proteins from those that are technically measurable only under selected conditions.

Affinity-based proteomics changes the scale of what can be tested, but it does not eliminate the biological complexity of urine. Protein concentrations in the specimen are influenced by nephron segment function, filtration barrier integrity, tubular uptake, urinary flow, and likely contributions from the lower urinary tract. A large panel can capture that complexity, but it also exposes the heterogeneity that smaller assays mask. The bimodal detectability pattern suggests that the urinary proteome contains a stable core alongside a wider peripheral set of proteins that may emerge only in particular biological states or under particular preanalytical circumstances.

For biomarker development, the message is straightforward even if the technology is not. A urinary protein candidate that is rarely measurable in a large CKD cohort may be difficult to move into practice without highly standardized conditions or a different assay format. By contrast, proteins with high detectability provide a more dependable foundation for reproducible testing. The study therefore does more than catalog proteins; it helps define the technical and biological terrain on which future urine biomarkers will either succeed or fail.

The reported counts also offer a reminder that proteome coverage and clinical usefulness are not identical. High-throughput panels can identify thousands of proteins, but the field still needs to separate analytic visibility from clinical signal. A protein that is easy to detect is not automatically useful. A protein that is difficult to detect is not automatically irrelevant. What matters next is how those proteins behave across kidney function strata, disease subtypes, and longitudinal follow-up, and whether any of them outperform existing urinary markers once the noise of sampling and assay variability is stripped away.

This urine proteome map should therefore be read as infrastructure for future nephrology research rather than as a finished diagnostic tool. It establishes a large-scale reference for what an affinity-based urinary assay can recover in a chronic kidney disease cohort and shows that the detectable urine proteome is organized unevenly, not uniformly. For investigators building the next generation of urinary biomarkers, that unevenness is not a minor technical footnote. It is the biological and analytic reality that will determine which signals can move from the lab into routine kidney care.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Kidney International.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA